Introgen Therapeutics, Inc. Presents Biomarker Data Predictive Of Therapeutic Efficacy At Annual Meeting Of The American Head And Neck Society

Introgen Therapeutics
(Nasdaq: INGN) announced today that molecular and clinical biomarker data
that can predict ADVEXIN therapeutic efficacy was selected for presentation
at the 2006 Annual Meeting of the American Head and Neck Society. Analyses
of predictive biomarkers defined subset populations of head and neck cancer
patients that may achieve the most benefit from ADVEXIN treatment. Dr.
Robert E. Sobol, Introgen's senior vice president of Medical and Scientific
Affairs, presented the data yesterday during the conference in Chicago.


Dr. Sobol discussed the identification of a set of prognostic
indicators associated with high response rates and increased survival in
Phase 2 clinical trials of Introgen's ADVEXIN therapy in patients with
recurrent squamous cell carcinoma of the head and neck. Biomarkers are
tests or measurements that predict response to treatment. Molecular
biomarkers include measurements of genetic markers or molecular pathways
while clinical biomarkers refer to clinical history or clinical
measurements. Application of these biomarkers can predict the patients who
are most likely to respond to ADVEXIN treatment. This information can be
utilized to guide ADVEXIN treatment of cancer patients and to support
approval of ADVEXIN for these patients by regulatory agencies.


The American Head and Neck Society (AHNS) Annual Meeting is the pre-
eminent location for head and neck specialists to present their clinical
research, to receive updates on the latest treatment techniques, and to
interact with colleagues within the specialty. The conference attendees
included approximately 750 physicians and researchers, including practicing
surgeons, clinical investigators, immunologists and molecular and cellular
biologists discussing developments for the prevention and treatment of head
and neck cancer.


Introgen Therapeutics, Inc. is a biopharmaceutical company focused on
the discovery, development and commercialization of targeted molecular
therapies for the treatment of cancer and other diseases. Introgen is
developing molecular therapeutics, immunotherapies, vaccines and
nano-particle therapies to treat a wide range of cancers using tumor
suppressors and cytokines. Introgen maintains integrated research,
development, manufacturing, clinical and regulatory departments and
operates multiple manufacturing facilities including a commercial scale
cGMP manufacturing facility.


Statements in this release that are not strictly historical may be
"forward-looking" statements, including those relating to Introgen's future
success with its clinical development program for ADVEXIN in the treatment
of head and neck cancer. The actual results may differ from those described
in this release due to risks and uncertainties that exist in Introgen's
operations and business environment, including Introgen's stage of product
development and the limited experience in the development of gene-based
drugs in general, dependence upon proprietary technology and the current
competitive environment, history of operating losses and accumulated
deficits, reliance on collaborative relationships, and uncertainties
related to clinical trials, the safety and efficacy of Introgen's product
candidates, the ability to obtain the appropriate regulatory approvals,
Introgen's patent protection and market acceptance, as well as other risks
detailed from time to time in Introgen's filings with the Securities and
Exchange Commission including its filings on Form 10-K and Form 10-Q.
Introgen undertakes no obligation to publicly release the results of any
revisions to any forward-looking statements that reflect events or
circumstances arising after the date hereof.


Editor's Note: For more information on Introgen Therapeutics, or for a
menu of archived press releases, please visit Introgen's Website at:
introgen.



Introgen Therapeutics, Inc.

introgen